VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 510 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2014. The put-call ratio across all filers is 1.37 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,481,000 | -40.9% | 102,000 | 0.0% | 0.94% | -38.8% |
| Q3 2016 | $2,504,000 | +21.9% | 102,000 | 0.0% | 1.54% | +24.0% |
| Q2 2016 | $2,054,000 | +41.9% | 102,000 | +85.5% | 1.24% | +37.2% |
| Q1 2016 | $1,447,000 | -80.8% | 55,000 | -25.7% | 0.90% | -79.6% |
| Q4 2015 | $7,522,000 | -15.3% | 74,000 | +48.6% | 4.43% | -19.5% |
| Q3 2015 | $8,880,000 | -28.0% | 49,784 | -10.3% | 5.51% | -18.5% |
| Q2 2015 | $12,326,000 | +11.9% | 55,484 | 0.0% | 6.76% | +10.5% |
| Q1 2015 | $11,020,000 | +38.8% | 55,484 | 0.0% | 6.12% | +29.0% |
| Q4 2014 | $7,940,000 | +9.1% | 55,484 | 0.0% | 4.74% | +3.6% |
| Q3 2014 | $7,280,000 | +22.3% | 55,484 | +17.6% | 4.58% | +15.3% |
| Q2 2014 | $5,953,000 | +100.7% | 47,200 | +109.8% | 3.97% | +62.7% |
| Q1 2014 | $2,966,000 | +12.3% | 22,500 | 0.0% | 2.44% | +22.6% |
| Q4 2013 | $2,641,000 | +12.5% | 22,500 | 0.0% | 1.99% | +7.6% |
| Q3 2013 | $2,347,000 | – | 22,500 | – | 1.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |